What Diosmin 500 Treats: Main Uses and Benefits

This medication is commonly used to provide supportive symptomatic relief for chronic venous disorders, particularly Chronic Venous Insufficiency (CVI). It is intended for use in situations where patients experience a distressing cluster of symptoms. The applications generally include managing symptoms related to venous circulation disorders and providing support during acute hemorrhoidal attacks.

For chronic venous issues, it may assist with easing symptoms such as the burdensome sensation of heavy legs, persistent aching, feelings of tension, and disruptive nighttime leg cramps. It is also relevant for managing venous edema, which presents as visible or palpable swelling in the lower extremities. In acute contexts, it is commonly used to help with managing the intensity of local discomfort, including pronounced pain and swelling.

“This support contributes to easing the overall symptom load and provides supportive relief when symptoms interfere with routine activities.”

This symptomatic assistance may help patients cope more steadily with these long-term or episodic manifestations.

Quick Fact: Support for Symptoms of Heavy Legs
Diosmin 500 is commonly used in conditions where venous symptoms are intensified by lifestyle factors, such as prolonged periods of standing or sitting.

Regulatory References

1. FDA Verification Portal (Daflon 500 Patient Information)

The eligibility profile is strictly defined by regulatory documentation for the Micronized Purified Flavonoid Fraction. The single absolute contraindication is hypersensitivity to the active substance (Diosmin/Hesperidin) or to any of the excipients; patients with this allergy must not use the medicine.

---

Age-Group and Physiological Status Eligibility

Use is officially established only for the adult population (18 years and older). Use is not established in children and adolescents under 18 years of age, as the safety and efficacy data for this group are unavailable in regulatory documents.

For women who are or may become pregnant, use is preferable to avoid as a precautionary measure, reflecting the limited official data on the medicine’s use. It is not recommended for women who are breast-feeding, as a risk to the newborn cannot be excluded. The official prescribing information does not contain specific restrictions or warnings regarding use in patients with hepatic (liver) or renal (kidney) impairment.

Interactions with other medicines and products

Official regulatory information for the Diosmin 500 combination generally reflects a consensus that no clinically relevant drug interaction has been reported from post-marketing surveillance and experience with the product. Furthermore, regulatory documentation often notes that no dedicated drug interaction studies have been performed for this specific fixed-dose formulation.

---

Official Regulatory Status

This absence of documented interaction studies and reports translates into the following profile regarding formal constraints and prohibitions in government-approved labeling:

Interaction Type	Officially Documented Status in Regulatory Labels
Specific Contraindicated Combinations	None documented.
Pharmacokinetic Interactions (e.g., CYP)	None documented. Explicitly noted that no studies have been performed.
Timing-based Separation Rules	None documented. No mandatory spacing from other medicines is required.
Interactions with Food or Alcohol	None documented. Some leaflets note interaction with food and drink as "Not applicable."
Population-specific Cautions	None documented. No specific notes for populations like hepatic impairment.

---

Profile Summary

The regulatory profile is structured around the finding that there are no defined drug-drug interaction requirements or specific prohibitions for co-administration detailed in the official prescribing information. Consequently, the labels do not stipulate mandatory timing separation from other treatments or list any medicines that require dose adjustments based on interaction risk.

Enhanced Venous Tone and Hemodynamic Regulation

The mechanism is driven by Diosmin's active metabolite, Diosmetin, which modulates the venous smooth muscle response to norepinephrine (noradrenaline). This action prolongs the natural vasoconstrictive signal, enhancing and sustaining the tension in the vein walls. The resulting physiological effect is an increase in venous tone, which contributes to a reduction in venous distension and pooling of blood volume in the peripheral circulation.

---

Microvascular Modulation and Anti-Inflammatory Action

The compounds modulate the capillary lining and vascular resistance. This is achieved by limiting the attachment and migration of inflammatory cells, such as neutrophils, through the down-regulation of adhesion molecules on the capillary endothelium. This mechanism results in a reduction of localized microvascular inflammation, thereby stabilizing the capillary structure and minimizing hyperpermeability (leakage) of fluid into the surrounding tissue.

---

Modulation of Lymphatic Drainage and Fluid Clearance

The formulation also modulates the peripheral lymphatic vessels, increasing the intrinsic frequency and force of their contractions. This enhancement of the lymphatic pump function supports the active removal of interstitial fluid and proteins. This activity modulates fluid dynamics, coordinating with the increased venous tone and stabilized capillary integrity to influence the accumulation of fluid volume in the tissues.

The administration of Diosmin 500 tablets, a fixed-dose combination, is structured according to the specific condition being addressed. The medication is intended for oral administration and is typically taken at mealtimes, usually midday and evening, to optimize intake conditions.

For managing symptoms related to Chronic Venous Disease (CVD), the standard regimen involves a dose of 1000 mg of the Micronized Purified Flavonoid Fraction (MPFF) daily, administered as two 500 mg tablets in divided doses. This usage pattern is often defined as long-term therapy.

In the case of an Acute Hemorrhoidal Attack, a short, intensive course is applied. The initial regimen consists of 3000 mg MPFF daily (six tablets) for the first four days, followed by a reduced, or tapering, dose of 2000 mg MPFF daily (four tablets) for the subsequent three days. This high-dose course is strictly short-term, limited to seven days.

Procedural and Population Rules

Rule Type	General Guidelines
Pediatric Use	Safety and efficacy have not been established for children and adolescents under 18 years of age.
Missed Dose	Patients should not take a double dose to compensate for a forgotten one.

The overall use protocol is defined by these two distinct, indication-specific regimens that dictate the appropriate dose, frequency, and duration patterns.

Research evidence / Overview of studies for Diosmin 500

---

Evidence for use in Chronic Venous Insufficiency Symptoms

This section summarizes the types of research studies, such as randomized trials and observational studies, that have examined Diosmin 500 as the subject of research in individuals with Chronic Venous Insufficiency (CVI).

Studies explored how outcomes related to physical discomfort were measured when Diosmin 500 was researched. These focused on symptoms common in conditions presenting with cycles of stability and flare-ups, such as swelling and the feeling of heavy legs. Research has explored the patterns of changes in CVI symptoms that were measured during the studies, and findings describe the changes observed over the short-term duration.

However, the follow-up durations were limited in many of the key trials. This means that while research provides insight into short-term changes, long-term effects are not fully established regarding the long-term characteristics of CVI symptoms.

---

Evidence for use in Hemorrhoidal Disease

This section reviews the structure of the available evidence base, including the types of clinical studies that have measured outcomes and observed observations in populations with acute and chronic hemorrhoidal disease.

Diosmin 500 was evaluated in research exploring outcomes capturing phases of heightened symptom activity associated with hemorrhoidal disease. The available data describe patterns related to symptom intensity and duration as monitored during the study periods. While research describes the experiences of groups studied, findings were mixed across some of the different trial designs.

---

What is still uncertain about Diosmin 500 Research

Research has primarily focused on the general adult population, meaning the results apply only to the populations studied. Data for special groups, such as pediatric populations or those with other significant medical conditions, remain insufficient.

Evidence quality varies across studies, leading to some inconsistency in the results. A major gap is the lack of long-term evidence; long-term effects are not fully established for either CVI or hemorrhoidal disease. Overall, the findings describe group patterns, not personal outcomes, and the evidence highlights where more research is needed.

Common questions about Diosmin 500 (FAQ)

---

Q: What are the storage instructions for the medicine?

Official product information generally advises that this medicine should be stored at room temperature. This range is generally considered to be between 20 C and 25 C (68 F and 77 F). Always check the packaging for specific storage conditions.

---

Q: Can I drink alcohol while taking this medication?

Official product information advises against the use of alcohol while taking this medicine. Alcohol consumption can increase the risk of certain central nervous system side effects, such as feelings of dizziness and sleepiness.

---

Q: Does this medicine cause sleepiness or drowsiness?

Yes, official product information for this medicine lists dizziness and somnolence (sleepiness) as potential common side effects. Patients should be aware that these effects may impair their ability to drive or operate machinery, and caution is generally advised.

---

Q: Is this medicine safe for me to use during pregnancy?

According to official product information, this medicine should be avoided during pregnancy unless a clear benefit exists that outweighs the potential risk to the fetus. The product information advises that the use of effective contraception is recommended for patients capable of becoming pregnant during treatment.

---

Q: Is it safe to take this medicine for a long period of time (long-term use)?

This medicine is indicated for managing conditions that may require extended treatment. Regulatory information emphasizes the need to avoid the abrupt or rapid discontinuation of the medicine, as this has been associated with withdrawal symptoms. Discontinuation, if necessary, should be done by gradually reducing the dosage over a minimum period of one week.

---

Q: Can children who are 2 years old use this medicine?

Based on the approved labeling in the United States, this medicine is approved as an add-on treatment for partial-onset seizures in patients 4 years of age and older. The medicine is not indicated for use in children who are 2 years old.

Storage and Disposal of Diosmin 500 mg

The required storage and disposal procedures for Diosmin 500 mg tablets are strictly defined in regulatory labeling to ensure product quality and public safety.

---

Official Storage Conditions

• Temperature: The medicine must be stored at temperatures not exceeding 30 C.
• Protection: The tablets must be kept in the original carton to shield them from environmental factors.
• Child Safety: It is mandatory to keep the product out of the reach and sight of children.
• Shelf Life: Do not use the tablets past the expiry date printed on the packaging.

---

Disposal Instructions

To prevent environmental contamination, unused or expired Diosmin 500 mg must not be thrown away with household trash or disposed of via wastewater (e.g., flushed down the toilet). The official instruction is to ask your pharmacist how to safely dispose of any unused product.